What is RiaSTAP used for?
Table of Contents
RiaSTAP is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency (CFD), including afibrinogenemia and hypofibrinogenemia.
How do I administer RiaSTAP?
Administer RIASTAP at room temperature by slow intravenous injection at a rate not exceeding 5 mL per minute. RIASTAP is available as a single-dose vial containing 900 mg to 1300 mg lyophilized fibrinogen concentrate powder for reconstitution with 50 mL of Sterile Water for Injection.
How is human fibrinogen administered?
Method of administration Intravenous infusion or injection. FIBRYGA should be administered slowly intravenously at a recommended maximum rate of 5 mL per minute for patients with congenital hypo- or afibrinogenaemia and at a recommended maximum rate of 10 mL per minute for patients with acquired fibrinogen deficiency.
How do I reconstitute RiaSTAP?
RiaSTAP (Fibrinogen concentrate (Human), FCH) is supplied as a white lyophilised powder in a one gram dosage form (1 g of human fibrinogen) to be reconstituted with 50 mL of Sterile Water for Injection. Once reconstituted, the solution contains 20 mg of fibrinogen per mL.
What is fibrinogen used for?
Fibrinogen is a protein produced by the liver. This protein helps stop bleeding by helping blood clots to form.
Is fibrinogen given IV?
RiaSTAP™ (fibrinogen concentrate (human) for intravenous use) , Fibrinogen Concentrate (Human) is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. For intravenous use only.
When do you give fibrinogen?
Indications for fibrinogen replacement therapy include the following conditions: Congenital disorders: Patients with congenital afibrinogenemia, hypofibrinogenemia, or dysfibrinogenemia, who present with clinically significant bleeding should be given fibrinogen concentrate to raise levels to 100-150mg/dL.
How does fibrinogen help clot blood?
When blood clotting is activated, fibrinogen circulating in the blood is converted to fibrin, which in turn helps to form a stable blood clot at the site of vascular disruption. Coagulation inhibitor proteins help to prevent abnormal coagulation (hypercoagulability) and to resolve clots after they are formed.
What is fibrinogen in pregnancy?
Fibrinogen is an essential agent involved in maintaining pregnancy and coagulation. Since inherited fibrinogen disorders introduce greater risks for conditions such as placental abruption and postpartum hemorrhage, careful prenatal and perinatal management is essential for this patient population.
What is RiaSTAP used to treat?
Indications and Usage for RiaSTAP. RiaSTAP ®, Fibrinogen Concentrate (Human) is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. RiaSTAP is not indicated for dysfibrinogenemia.
Is RiaSTAP contraindicated in patients with anaphylaxis?
RiaSTAP ®, Fibrinogen Concentrate (Human), is contraindicated in patients with known anaphylactic or severe systemic reactions to human plasma-derived products. Monitor patients for early signs of anaphylaxis or hypersensitivity reactions and if necessary, discontinue administration and institute appropriate treatment.
What is the composition of RiaSTAP?
RiaSTAP is a heat-treated, lyophilized fibrinogen (coagulation factor I) powder made from pooled human plasma. Each vial contains 900 to 1300 mg fibrinogen, 400 to 700 mg human albumin, 375 to 660 mg L-arginine hydrochloride, 200 to 350 mg sodium chloride and 50 to 100 mg sodium citrate.
How do you administer RiaSTAP?
Administer RiaSTAP at room temperature by slow intravenous injection at a rate not exceeding 5 mL per minute. RiaSTAP is available as a single-dose vial containing 900 mg to 1300 mg lyophilized fibrinogen concentrate powder for reconstitution with 50 mL of Sterile Water for Injection.